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PVIEWPOINT AND COMMENTARY
Statins in Acute Coronary Syndromes
Do the Guideline Recommendations Match the Evidence?
Ryan P. Morrissey, MD,* George A. Diamond, MD,*‡ Sanjay Kaul, MD*†§
Los Angeles, California
On the basis of the evidence obtained from observational studies, randomized controlled trials and their
meta-analyses, current guidelines recommend initiating high-dose statin therapy pre-discharge regardless of
the baseline low-density lipoprotein (LDL) level in patients with acute coronary syndromes (ACS). Careful review
of the evidence indicates that early initiation of high-dose statin therapy reduces recurrent ischemia and may
reduce revascularization, but does not confer benefit in terms of hard clinical outcomes such as death or myo-
cardial infarction in any of the randomized controlled trials, and may be associated with increased liver and
muscle-related adverse outcomes leading to increased withdrawal and suboptimal long-term adherence. A mor-
tality benefit is apparent in pooled analyses of randomized controlled trials only at long-term (24-month) but not
short-term (4-month) follow-up. The critical role of the timing of initiation of therapy (early vs. late) on the
benefit-risk profile of statin treatment has not been systematically assessed. It is unclear whether the clinical
benefits are attributable to lipid-lowering or lipid-lowering–independent effects. Finally, an optimal LDL threshold
for initiating treatment or target LDL level for treatment in ACS remains yet to be defined. On the basis of these
observations, and despite a compelling pathophysiologic rationale, the justification for current Class I, Level of
Evidence: A recommendation for statin therapy in patients with ACS remains open to question. (J Am Coll Car-
diol 2009;54:1425–33) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.093E
S
r
a
(
p
a
T
(
m
t
h
b
i
i
w
t
s
g
p
r
A
S
w
a“There are no facts, only interpretations.”
—Friedrich Nietzsche (1)
ach year, nearly 1.5 million people living in the U.S. suffer
n acute coronary syndrome (ACS) (2). The administration
f aspirin, beta-blockers, and angiotensin-converting en-
yme inhibitors in patients during ACS has been shown to
e beneficial (3–5). The evidence supporting the use of
tatins, however, is less clear (6).
Statins clearly reduce cardiovascular mortality and mor-
idity in primary and secondary prevention of coronary
eart disease (CHD) (7). A majority of the secondary
revention trials have been limited to the timeframe imme-
iately (3 to 6 months) following an index acute coronary
vent (7). Consequently, over the past decade, a number of
nvestigations have specifically evaluated the role of statins
uring the course of ACS. Based on the results of these
nvestigations, early intensive statin therapy has become
ormally endorsed as a treatment guideline (3,4) and a
erformance measure (5) in patients with ACS. We herein
eview the evidence base in support of these policy
ecommendations.
rom the *Cedars-Sinai Medical Center, †Division of Cardiology, ‡David Geffen
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nd the §Cedars-Sinai Heart Institute, Los Angeles, California. Dr. Diamond serves
n the speaker’s panel of Schering-Plough and Merck.m
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009, accepted April 14, 2009.fficacy of Statin Therapy
tatins exhibit a number of biologic effects that may be
elevant in the setting of acute ischemic events (8). They
ct rapidly to improve vascular endothelial function
8 –10), attenuate vascular inflammation (8,11), stabilize
laques (12), correct prothrombotic tendencies (8,12),
nd influence myocardial protection and remodeling (13).
hese effects may be related to low-density lipoprotein
LDL) reduction or to a variety of LDL-independent
echanisms—the so-called pleiotropic effects. The rela-
ive importance of these 2 mechanisms continues to be
otly debated.
A meta-regression analysis found that the nonstatin (diet,
ile acid sequestrants, and ileal bypass surgery) and statin
nterventions in stable patients appear to reduce CHD risk
n a similar manner, consistent with the 1-to-1 relationship
ith the degree of LDL cholesterol lowering (14). This is
rue for the ACS trials as well. For example, despite
ignificant reductions in inflammatory markers, a 31%
reater reduction in LDL with atorvastatin 80 mg over
ravastatin 40 mg was associated with an additional 18%
eduction in CHD events in the PROVE-IT (Pravastatin or
torvastatin Evaluation and Infection Therapy) trial (15).
imilarly, a 14% greater reduction in LDL was associated
ith a 12% better outcome in the aggressive statin treatment
rm in the A to Z (Aggrastat to Zocor) trial (16). A
eta-analysis of placebo-controlled trials found that statin
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Statins in ACS Revisited October 6, 2009:1425–33therapy had no significant effect on
C-reactive protein, an inflamma-
tory biomarker, after adjustment
for change in LDL (17). Multivar-
iate modeling revealed that only
2% to 11% of the C-reactive pro-
tein change (28% reduction) could
not be accounted by LDL lower-
ing. Thus, these results provide
insufficient evidence in support of
the pleiotropic effects of statins.
Nevertheless, the role of statin therapy in patients with
CS relies more on empirical observation than on mecha-
ism of action. The efficacy of statin therapy in ACS has
een evaluated in observational studies, post-hoc analyses of
CS clinical trials performed for other purposes, placebo-
r active-controlled randomized controlled trials and their
eta-analyses. The results of key trials and meta-analyses
re summarized in Table 1.
bservational studies. A number of observational studies
ndicate that statins decrease major cardiovascular outcomes
ncluding mortality by approximately 30% to 40% in treat-
ent subjects compared with control subjects when initiated
efore or at discharge after ACS (18–24). In a large
wedish registry, RIKS-HIA (Register of Information and
nowledge about Swedish Heart Intensive Care Admis-
ions), of nearly 20,000 cardiac intensive care patients,
reatment with a statin was associated with significantly
ower 1-year mortality (adjusted relative risk: 0.75, 95%
onfidence interval [CI]: 0.63 to 0.89) (19). These obser-
ations were confirmed in a pooled analysis of the GUSTO-
Ib (Global Utilization of Streptokinase and TPA for
ccluded Arteries IIb) plus PURSUIT (Platelet Glycopro-
ein IIb/IIIa in Unstable Angina: Receptor Suppression
sing Integrilin Therapy) trials enrolling about 20,000
atients (adjusted mortality hazard ratio [HR]: 0.67, 95%
I: 0.48 to 0.95) (25), the NRMI (National Registry of
yocardial Infarction) 4 database (adjusted in-hospital
ortality odds ratio [OR]: 0.58, 95% CI: 0.54 to 0.63) (22),
nd Nagashima et al. (24) that demonstrated sustained
ortality benefit at 5-year follow-up. The benefit associated
ith early initiation of statin therapy documented in the
MRI-4 registry coupled with the harm associated with
uddenly stopping statins after an ACS documented in the
MRI-4 registry (22) and the PRISM (Platelet-Receptor
nhibition for Ischemic Syndrome Management) study (26)
urther highlight the efficacy of statin treatment. In contrast,
ooled analysis of the first and the second SYMPHONY
Sibrafiban Versus Aspirin to Yield Maximum Protection
rom Ischemic Heart Events Post-Acute Coronary Syn-
romes) trials found no improvement in outcomes (adjusted
ortality HR: 0.99, 95% CI: 0.73 to 1.33) (27). The
nconsistency among these observational studies is likely
elated to confounding arising from nonrandomized com-
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
CHD  coronary heart
disease
LDL  low-density
lipoprotein
MI  myocardial infarctionarisons and heterogeneity in the timing of statin therapy. tandomized trials. Several placebo-controlled (28–35)
nd 2 active-control randomized trials (15,16) have evalu-
ted the efficacy and safety of statins in ACS. With the
xception of the MIRACL (Myocardial Ischemia Reduc-
ion with Aggressive Cholesterol Lowering) trial (32), none
f the placebo-controlled trials showed a significant reduc-
ion in the primary end point. These studies were, however,
imited by insufficient statistical power to detect differences
ver placebo due to premature study termination as a
onsequence of slow enrollment in the PACT (Plasminogen
ctivator-Angioplasty Compatibility Trial) (33), statin
ithdrawal in the PRINCESS (Prevention of Ischaemic
vents by Early Treatment of Cerivastatin after Acute
yocardial Infarction) trial (34), or low event rates in the
LORIDA (Fluvastatin on Risk Diminishing After Acute
yocardial Infarction) trial (35). In the MIRACL study,
he reduction in the primary composite end point was driven
y recurrent angina requiring hospitalization without sig-
ificant effects on death, cardiac arrest, myocardial infarc-
ion (MI), or revascularization (32). Furthermore, an un-
lanned interim analysis was performed in the MIRACL
rial without adjustment of p value in the reported results
p  0.048). Whether the primary end point would have
eached statistical significance had such an adjustment been
ade remains unclear.
eta-analyses. A meta-analysis of 12 trials comparing
arly statin therapy with placebo or usual care demonstrated
hat initiation of statin therapy within 14 days following
nset of ACS did not reduce death, MI, or stroke at 4
onths of follow-up (6). Additional meta-analyses of ran-
omized controlled trials demonstrate that early initiation of
tatins after ACS improves cardiovascular outcomes, al-
hough these benefits take 6 months for morbid events (36)
nd 24 months for fatal events (36,37) to become evident.
afety of Statin Therapy
oderate doses of statins are generally safe and well
olerated (Table 1). Regarding the safety of high-dose
tatins used in ACS trials, higher doses of simvastatin were
ssociated with a greater incidence of myopathy compared
ith lower doses in the A to Z trial (Table 1), a finding also
bserved in the SEARCH (Study of the Effectiveness of
dditional Reductions in Cholesterol and Homocysteine)
tudy, a recent trial of aggressive versus moderate LDL
owering in more than 12,000 heart attack survivors (38).
here were 53 cases of myopathy reported with 80-mg
imvastatin compared with only 3 cases with 20-mg simva-
tatin. Similarly, a greater incidence of liver enzyme eleva-
ion was seen with 80 mg/day of atorvastatin compared with
0 mg/day of pravastatin in the PROVE-IT study (15). In
he MIRACL study, there was a statistically significant
-fold increase in liver enzyme elevations with 3 cases of
epatitis (2 of them resolving upon discontinuation) (32).
eta-analyses of intensive- versus moderate-dose statinrials reveal a 2- to 4-fold increase in adverse hepatic and
Randomized Control Trials and Meta-Analyses of Statin Therapy Initiated for ACSTable 1 Randomized Control Trials and Meta-Analyses of Statin Therapy Initiated for ACS
Trial (Ref. #) Treatment
Initiation, Days
(Mean)
Primary
End Point
Follow-Up,
Months
On-Treatment
LDL
(mg/dl)
Efficacy
Safety
ALT (>3 ULN) CK (>10 ULN)
Control Rx
Control
(%)
Rx
(%)
Odds Ratio
(95% CI)
Control
(%)
Rx
(%)
Odds Ratio
(95% CI)
Control
(%)
Rx
(%)
Odds Ratio
(95% CI)
Randomized Control Trials
MIRACL (32) Atorvastatin 80 mg
vs. placebo
1–4 (2.6) Death, MI, cardiac
arrest, RI
4 135 72 17.4 14.8 0.84 (0.7–1.00) 0.6 2.5 4.33 (2.09–8.99) 0 0 Not estimable
A to Z (16) Simvastatin 40/80
mg vs. placebo/
simvastatin
20 mg
5 (3.7) CV death, MI,
stroke, ACS
24 81 66 16.7 14.4 0.89 (0.76–1.04) 0.36 0.84 2.35 (1.03–5.38) 0.04 0.40 8.90 (1.13–70.28)
PROVE-IT (15) Atorvastatin 80 mg
vs. pravastatin
40 mg
10 (5.7) Death, MI, RI,
revasc, stroke
24 95 62 26.3 22.4 0.84 (0.74–0.95) 1.1 3.3 3.01 (1.87–4.85) 0.15 0.10 0.65 (0.11–3.92)
Meta-Analyses
Briel et al. (6) (12 RCTs) Statin vs. placebo 14 (4.3) Death, MI, stroke 4 137 110 7.5 8.1 0.93 (0.81–1.07) 0.4 1.1 NA 0.06 0.1 NA
Bavry et al. (37)
(7 RCTs)
Early intensive
statin vs. control
12 (5.3) Death 24 121 86 4.6 3.3 0.75 (0.61–0.93) 0.56 1.6 2.93 (2.09–4.09) 0.71* 0.97* 1.35 (0.96–1.89)
MI† 24 7.0 6.6 0.94 (0.81–1.09)
Stroke† 24 1.2 1.1 0.90 (0.62–1.30)
RI† 24 5.0 4.1 0.81 (0.68–0.98)
Revasc† 24 12.9 11.2 0.86 (0.78–0.96)
Afilalo et al. (40)
(PROVE-IT  A to Z)
Intensive vs.
moderate statin
10 (4.7) CV death, ACS,
stroke
24 89 64 24.8 22.0 0.86 (0.73–1.01) 0.72 2.0 2.83 (1.88–4.27)‡ 0.02 0.21 8.87 (1.12–70.07)‡
Death† 24 4.6 3.5 0.75 (0.61–0.93)
*Reported as myositis; †secondary end point; ‡pooled analysis. Efficacy refers to the primary end point.
ACS acute coronary syndrome; CI confidence interval; CV cardiovascular; MImyocardial infarction; NA not available; RCT randomized control trial; Revasc coronary artery bypass graft surgery or percutaneous coronary intervention; RI recurrent ischemia
requiring hospitalization; Rx  prescription; ULN  upper limit of normal.
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Statins in ACS Revisited October 6, 2009:1425–33uscular events, and an increase in adverse events requiring
iscontinuation of therapy (39–41). In general, the upward
itration of statins from 40 to 80 mg is associated with
ultiple-fold increases in liver or muscle toxicity (likely
ontributing to lower adherence) while providing only 6% to
% additional LDL reduction (reflecting the log-linear
elationship between LDL reduction and statin dose)
Table 1). Moreover, adverse event rates in real-world
linical practice are likely substantially higher (42) than
hose reported in clinical trials because of the strict exclusion
riteria and run-in phase employed in trials that “filter out”
atients intolerant to statins.
uidelines for Statin Therapy in ACS
urrent American College of Cardiology/American Heart
ssociation (ACC/AHA) guidelines provide a Class I,
evel of Evidence: A (strong and compelling evidence in
avor of benefit outweighing the risk) recommendation for
nitiating statin therapy pre-discharge regardless of the
aseline LDL level (3,4). Furthermore, the guidelines also
rovide a Class I, Level of Evidence: A recommendation for
DL target of 100 mg/dl and Class IIa, Level of Evi-
ence: A (reasonable but high-quality evidence) for LDL
arget of 70 mg/dl in ACS (3,4). Let us examine whether
hese guideline recommendations are supported by evidence.
iming of statin therapy. The critical role of the timing of
nitiation of statin therapy (i.e., early vs. late during hospi-
alization or pre- vs. post-discharge) has been formally
valuated in only 2 observational studies and 1 randomized
ontrolled trial.
Li et al. (43) compared patients started on statin therapy
2 days versus 2 days after admission for first episode of
CS. After multivariate analysis, there was no significant
nfluence on the primary end point at 4 months or at 12
onths. Similarly, Saab et al. (44) observed no significant
ifferences in cardiovascular outcomes at 6 months in
atients receiving statin therapy 24 h versus 24 h after
dmission. These observational data do not suggest a
reatment advantage for initiating statin treatment within
4 to 48 h of admission for ACS.
The randomized clinical trial A to Z (16) compared early
ntensive to delayed conservative statin therapy in patients
ith ACS. Patients were randomized within 5 days of
dmission to simvastatin 40 mg/day for 1 month followed
y simvastatin 80 mg/day versus placebo for 4 months
acute phase) followed by simvastatin 20 mg/day thereafter
chronic phase). No significant differences in outcomes were
bserved either during the acute phase (primary end point
R: 1.01, 95% CI: 0.83 to 1.25) or at 24 months (HR: 0.89,
5% CI: 0.76 to 1.04). However, the trial was limited by
nsufficient power as fewer than expected events were
ccrued in the trial (652 instead of the planned 970) (16).
reatment threshold. The influence of baseline pre-
reatment LDL on the clinical benefit of lipid-lowering
herapy remains controversial. Two observational studies beported favorable outcomes in patients prescribed statin
reatment at discharge even in those with LDL levels 100
45) or 60 mg/dl (46). In contrast, randomized controlled
rials have shown inconsistent results. A post hoc analysis of
he CARE (Cholesterol And Recurring Events) trial found
o significant benefit of LDL lowering with 40-mg prava-
tatin in individuals whose baseline LDL levels were 125
g/dl (47). However, in a post hoc analysis of the HPS
Heart Protection Study) trial, significant benefits were seen
n high-risk individuals even when their baseline LDL levels
ere low, that is, 100 mg/dl (48). Data from intensive-
ersus moderate-LDL lowering trials provide inconsistent
nformation in this regard. A threshold relationship was
een in the TNT (Treatment to New Targets) study (34%
eduction in those with baseline LDL 125 mg/dl com-
ared with 7% reduction in those with LDL 125 mg/dl)
49) and the PROVE-IT trial (37% reduction in those with
aseline LDL 132 mg/dl compared with 7% reduction in
hose with LDL 92 mg/dl) (50), but not in the IDEAL
Incremental Decrease in Endpoints through Aggressive
ipid Lowering) study (51). In the PROVE-IT (50) and
USASHI-AMI (Multicenter Study for Aggressive Lipid-
owering Strategy by HMG-CoA Reductase Inhibitors in
atients with Acute Myocardial Infarction) (31) trials, the
enefit of intensive therapy progressively declined as base-
ine LDL cholesterol decreased. A post hoc multivariable
nalysis of the PROVE-IT trial revealed no evidence of
enefit in patients with baseline LDL 66 mg/dl (50). A
eta-analysis of data from 90,056 patients in 14 trials
ndicated that the treatment benefit associated with statin
as not shown to be related to baseline pre-treatment LDL
evel but to the reduction in LDL levels—a 40-mg/dl
eduction in LDL translating into a 20% improvement in
utcomes (7). A key limitation is that in none of these trials
ere patients randomized to statin therapy according to low
nd high pre-treatment LDL levels. Thus, the guideline
ecommendation for initiating statin therapy in ACS re-
ardless of the baseline LDL level reflects the current
mphasis on risk stratification-based rather than an LDL
evel-driven approach to treating dyslipidemias. The justi-
cation for this approach, however, is based on extrapola-
ion from epidemiologic observations, post hoc review of
rial data, expert opinion, and a belief in pleiotropic effects
f statins rather than an evidence-based conclusion derived
rom prospective randomized controlled trials.
reatment target. The current ACC/AHA guideline rec-
mmendations for statin treatment target were adapted
rom LDL targets proposed by National Cholesterol Edu-
ation Program guidelines that offer an “optional” LDL goal
f 70 mg/dl for patients believed to be at very high risk of
therosclerotic heart disease such as ACS and a “mandatory”
ess ambitious target LDL goal of 100 mg/dl for standard
igh-risk patients (52). The scientific validity of these
argets, particularly the ultralow LDL target of 70 mg/dl,
as been challenged recently by Hayward et al. (53) as not
eing based on compelling evidence. Further, they also
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October 6, 2009:1425–33 Statins in ACS Revisitedemain unconvinced about the evidence previously cited to
upport an LDL goal of 100 mg/dl for high-risk patients,
ointing out several methodological limitations such as
ailure to account for known confounders such as a “healthy
olunteer” effect, post-randomization analysis based on
bservational cohort data, lack of randomization to achieved
DL targets, failure to consider pleiotropic effects of statins,
nd flaws intrinsic to ecological analyses that drive the
uideline recommendations (53). The supporters of the
uideline recommendations counter these criticisms by cit-
ng a vast body of favorable evidence derived from clinical
rials, epidemiological data, anthropological data (54) and
xperimental laboratory data that cannot be ignored.
A critical examination of the data indicates that although
ngiographic (55), intracoronary ultrasound (56) and carotid
ntima-media thickness (57) studies have generally shown
hat lowering LDL to very low levels arrests or even reverses
he development of atherosclerosis (a surrogate outcome),
here is very little clinical outcome data to support the
lower is-better” hypothesis.
The results of trials of intensive lipid lowering with
igh-dose statin therapy versus moderate lipid lowering
ith standard-dose statin therapy—the subject of 5 ran-
omized controlled trials, 2 in patients with ACS
PROVE-IT [15], A to Z [16]) and 3 in patients with
table CHD (TNT [49], IDEAL [51], SEARCH [38])—
rovide important insights. None of these trials was de-
igned to address the “treat to target” hypothesis but they
sed a fixed dose of statin (high- vs. standard-dose)
hroughout. Two of the five trials compared nonequipotent
oses of different statins (PROVE-IT and IDEAL). Pooled
re-treatment LDL averaged 130 mg/dl and post-treatment
DL averaged 101 and 75 mg/dl with moderate- and
omparison of PROVE-IT and A to Z Trials of Early Intensive StatinTable 2 Comparison of PROVE-IT and A to Z Trials of Early Inte
Variable PROVE-IT (n 
Treatment Atorvastatin 80 mg vs. p
Placebo-controlled phase No
Trial design Active-control no
Time of statin initiation, mean (days) 5.7
Follow-up, yrs 2
Primary end point Death, MI, hospitalization fo
revascularization,
U.S. enrollment 71%
Age, mean (yrs) 58
Females 22%
History of diabetes 18%
Hypertension 50%
Smoker 36%
Prior history of CHD 18% MI, 38% CHD, 15%
Previous statin use 25%
Index event 29% UA, 36% NSTEM
PCI for index event 69%
Death rate 2.2% vs. 3
Death or MI rate 8.3% vs. 1ABG  coronary artery bypass graft surgery; CHD  coronary heart disease; NSTEMI  non–ST-segment
levation myocardial infarction; UA  unstable angina; other abbreviations as in Table 1.ntensive-dose treatment, respectively (39). The guideline-
ecommended LDL target of 70 mg/dl was achieved in
he 2 ACS trials—median LDL of 62 mg/dl in the
ROVE-IT trial on atorvastatin 80 mg/day (15), 66 mg/dl
n the A to Z trial on simvastatin 80 mg/day (16) (Table 1).
he primary end point was significantly reduced in favor of
ntensive therapy in 2 out of the 5 trials (PROVE-IT and
NT), mostly driven by reductions in revascularization or
nstable angina requiring hospitalization in the PROVE-IT
rial (which constituted 75% of the composite end point)
15) and nonfatal MI or stroke in the TNT study (49).
ooled analyses of randomized controlled trials of intensive
ersus moderate LDL lowering failed to reveal a benefit in
ll-cause or cardiovascular mortality (39–41). Although
ntensive-dose statin therapy was associated with a reduced
isk for important cardiovascular events, it was also associ-
ted with an increased risk for statin-induced adverse
vents. Pooling the results of only ACS trials (A to Z and
ROVE-IT), Afilalo et al. (40) reported a reduction in
ll-cause mortality from 4.6% to 3.5% over 2 years (OR:
.75, 95% CI: 0.61 to 0.93) with intensive statin therapy.
imilar observations were also reported by Josan et al. (58).
espite lack of statistical heterogeneity, there is substantial
linical heterogeneity between the 2 trials with respect to
rial design, patient characteristics, treatment protocols, and
utcome event rates (Table 2) that argue against pooling,
hereby challenging the interpretability of the pooled data.
The results from the PROVE-IT trial have been inter-
reted as providing strong support for aggressive LDL
owering. There are, however, several issues with the design
nd analysis of the PROVE-IT trial that merit careful
onsideration. First, the PROVE-IT trial was not designed
o prospectively address the “lower-is-better” hypothesis,
apy in ACSStatin Therapy in ACS
2) A to Z (n  4,497)
tatin 40 mg Simvastatin 40/80 mg vs. simvastatin 0/20 mg
Yes
ority Active-control superiority, factorial design
3.7
2
rrent ischemia,
troke
CV death, MI, stroke, readmission for ACS
21%
61
24%
24%
50%
41%
11% CABG 17% MI, 45% PCI, 4% CABG
0%
STEMI 40% STEMI, 60% NSTEMI
44%
5.5% vs. 6.7%
11.1% vs. 12.4%Thernsive
4,16
ravas
ninferi
r recu
and s
PCI,
I, 35%
.2%
0.0%elevation myocardial infarction; PCI  percutaneous coronary intervention; STEMI  ST-segment
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Statins in ACS Revisited October 6, 2009:1425–33hat is, an LDL reduction of 50% would be more beneficial
han an LDL reduction of 25%. To the contrary, the
rimary hypothesis of the trial was to show that moderate
ipid lowering with standard-dose pravastatin would be “not
uch worse” (noninferior) than aggressive lipid lowering
ith high-dose atorvastatin. In science, hypothesis should
e fixed a priori and tested rather than assumed (hypothesis
hould drive the data and not vice versa). Second, the
ifference in favor of aggressive LDL lowering with ator-
astatin was largely driven by reduction in soft end points of
ecurrent angina and revascularization (the most prevalent
omponents of the composite end point) with a nonsignif-
cant impact on the hard end points of death, MI, or stroke.
hird, the fact that 2 different statins (atorvastatin 80 mg vs.
ravastatin 40 mg) with slightly different effects on the lipid
rofile and possibly different pleiotropic properties were
sed makes it difficult to ascertain whether all differences
etween the 2 regimens can be explained by the intensity of
ipid lowering. Finally, post-hoc analysis of the 4-month
ata in the PROVE-IT trial has been argued to indicate
hat further benefit is conferred without additional risk for
dverse events when LDL is reduced to 40 to 60 mg/dl
ompared with 61 to 80 mg/dl (59). However, 30% of the
atients discontinued drug therapy prematurely, which
ight have contributed to the reported low rate of side
ffects. In addition, lack of adequate power to detect adverse
vents and residual confounding challenge the interpreta-
ion of the results. A post hoc analysis of 2-year data in the
ROVE-IT trial failed to reveal significant differences in
he primary end points in patients with median follow-up
DL concentrations of 53 mg/dl versus 82 mg/dl (50).
herefore, the intensity of statin therapy and the associated
arget threshold of LDL reduction at which the benefits still
utweigh potential adverse effects remain open to question.
hus, it can be argued that the results from the PROVE-IT
rial do not provide unequivocal evidence in support of the
lower-is-better” hypothesis.
Based on these observations, there is insufficient evidence
o recommend treating to particular LDL targets as advo-
ated by the guidelines. It is interesting to note that the
uropean Society of Cardiology guideline recommenda-
ions for statin treatment in ACS are less sanguine than the
CC/AHA guidelines. They recommend early initiation
within 1 to 4 days) of statin treatment with the aim of
chieving LDL levels 100 mg/dl (Class I, Level of
vidence: B), and intensive lipid-lowering therapy with
arget LDL levels 70 mg/dl initiated within 10 days after
dmission (Class IIa, Level of Evidence: B) (60). Implicit in
he Level of Evidence: B recommendations (compared with
evel of Evidence: A recommendations endorsed by the
CC/AHA guidelines) is the acknowledgment of lack of
high-quality” evidence in support of LDL treatment tar-
ets.
Finally, an analysis of existing data from primary and
econdary prevention trials, including the ACS trials, could
rovide useful insights into the threshold and target issuesy documenting the multivariate relationship (or lack
hereof) of clinical outcome to baseline LDL and magnitude
f LDL reduction. One such hypothetical analysis, demon-
trating a graded relationship of treatment benefit according
o tertiles of baseline LDL (from 70 to 100 mg/dl) and
uartiles of percent LDL lowering (from 10% to 30%),
s illustrated in Figure 1. We urge those with access to these
ata to conduct such analyses. However, given the lack of
andomization according to LDL treatment thresholds or to
chieved LDL targets in these trials, it is important to keep
n mind the exploratory nature of such analyses and the
imited ability to draw inferences from them. Only random-
zed controlled trials that are properly designed to prospec-
ively evaluate LDL threshold and LDL target can provide
ore valid and persuasive evidence in support of guideline
ecommendations to inform clinical practice.
tatin Adherence After ACS
t has been argued that perhaps the most important reason
o initiate statin therapy during the hospital phase of the
CS is to ensure that patients receive this critical compo-
ent of secondary prevention and to improve long-term
dherence by taking advantage of a “teachable moment”
hen patients are most motivated. Recent registry and
bservational cohort studies such as the NMRI-4 registry
20) and the CHAMP (Cardiac Hospitalization Athero-
clerosis Management Program) (61) and LTAP (Lipid
reatment Assessment Project) (62) trials have demon-
trated improved short- and long-term adherence rates
hen statins, along with other cardioprotective medications,
ere started early before hospital discharge. However, these
tudies were limited by lack of randomization and lack of
igh-dose statin treatment. The drop-out rate associated
ith high-dose statin treatment in randomized trials is not
rivial—nearly 11% over 4 months in the MIRACL trial
32) and nearly 30% over 2 years in both the PROVE-IT
Figure 1 CHD Risk Reduction According
to Baseline LDL-C and LDL Lowering
Putative relationship of treatment benefit (% coronary heart disease [CHD] risk
reduction) according to baseline pre-treatment LDL (from 70 to 100 mg/dl)
and % low-density lipoprotein (LDL) lowering (from 10% to 30%). LDL-C 
low-density lipoprotein cholesterol.
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October 6, 2009:1425–33 Statins in ACS Revisited15) and A to Z trials (16). Treatment intolerance and
ithdrawal rates in real-world clinical practice may be even
igher than those reported in clinical trials (63,64). Thus,
here is no direct evidence in support of improved adherence
ith early intensive statin therapy. Nevertheless, one could
till make a case for initiating a low- or moderate-dose statin
uring hospitalization and up-titrating to achieve desired
arget LDL levels during subsequent post-hospitalization
ollow-up. This might help optimize adherence (65) and
reserve the benefits associated with long-term statin ther-
py while minimizing the potential for adverse events.
mplications
n objectively reviewing the evidence on statins in ACS, it is
mportant not to miss the forest for the trees. The rationale
or statins in ACS is supported by a large body of evidence
erived from basic laboratory, epidemiologic, and clinical
rial data. Although “unequivocal” trial evidence in support
f guideline recommendations is arguably lacking at the
urrent time, and because there is the possibility of benefit
ith little or no likelihood of harm in most patients, it is
ard not to acknowledge an important role for statin
herapy in ACS. It is prudent to recommend low-to-
oderate-dose statin therapy as the most appropriate choice
or achieving cardiovascular risk reduction in the majority of
ndividuals without incurring adverse effects, whereas
ntensive-dose statin therapy may be reserved for those that
o not respond to low-to-moderate-dose statins. However,
he challenges of obtaining LDL goals in clinical practice
ompared with clinical trials where less than one-half of the
atients achieved LDL 70 mg/dl) (15,16,49,51) and the
enefit-risk-cost ratio of aggressive LDL lowering strategy
n clinical practice (frequent use of multidrug therapy with
ts potential harms, frequent monitoring, adherence, and so
n) cannot be overlooked.
onclusions
n acute coronary syndromes, early initiation of high-dose
tatin therapy reduces recurrent ischemia; may reduce re-
ascularization, but does not confer benefit in terms of the
ard clinical outcomes of MI and stroke; and may be
ssociated with increased liver and muscle-related adverse
utcomes leading to increased withdrawal and suboptimal
ong-term adherence. A mortality benefit is apparent in
ooled analyses of trials only at long-term (24-month) but not
t short-term (4-month) follow-up. Both clinical benefit and
dverse safety outcomes appear to be dose- and statin-
ependent. It is unclear whether the clinical benefits are
ttributable to lipid-lowering or lipid-lowering-independent
ffects. The critical role of the timing of initiation of therapy
early vs. late) on the benefit-risk profile of statin treatment has
ot been systematically assessed. Finally, an optimal LDL
hreshold for initiating treatment and a target treatment LDL
1evel in ACS remain to be defined. On the basis of these
bservations, and despite a compelling pathophysiologic ratio-
ale, the current evidence is insufficient to justify a Class I,
evel of Evidence: A recommendation (as formerly defined)
or initiating with ACS. More importantly, these limitations
lso call into question the recent elevation of this guideline to
performance measure (5), which is typically reserved for the
ighest level of evidence.
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PPENDIX
earch methodology. We searched EMBASE, MEDLINE,
nd the Cochrane Library until March 3, 2009. We used
he following terms: statin(s), HMG-CoA reductase inhib-
tor(s), acute coronary syndrome(s), myocardial infarc-
ion(s), low-density lipoprotein (LDL), adherence, compli-
nce, and guidelines. We focused on the randomized
ontrolled trials and their meta-analyses, nonrandomized
valuations, editorials, and reviews to explore key issues
elating to statins in acute coronary syndromes. All articles
ere limited to the English language.
